Subsequent Events (Details) |
1 Months Ended | 3 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
Aug. 01, 2026
USD ($)
|
Jul. 14, 2026
USD ($)
|
Jul. 28, 2026
USD ($)
|
Sep. 30, 2026
USD ($)
|
Aug. 06, 2026 |
Jul. 27, 2026
USD ($)
|
Jul. 01, 2026 |
Jun. 30, 2026 |
Nov. 30, 2022 |
|
| Research Collaboration and Co-Development Agreement | |||||||||
| Subsequent Event | |||||||||
| Collaboration agreements cost sharing percentage (as a percent) | 50.00% | 50.00% | |||||||
| Subsequent Event | |||||||||
| Subsequent Event | |||||||||
| Restructuring cost | $ 2,400,000 | ||||||||
| Area of lease terminated | 39,432 | ||||||||
| Area of land leased | 29,864 | 69,296 | |||||||
| Lease termination fee | $ 800,000 | ||||||||
| Sale of asset, cash consideration | $ 500,000 | ||||||||
| Gain (loss) on disposal of assets | $ 0 | ||||||||
| Subsequent Event | Research Collaboration and Co-Development Agreement | LigaChem Biosciences | |||||||||
| Subsequent Event | |||||||||
| Collaboration agreements cost sharing percentage (as a percent) | 100.00% | 50.00% | |||||||
| Subsequent Event | Avere Therapeutics, Inc. | |||||||||
| Subsequent Event | |||||||||
| Aggregate purchase price | $ 320,000,000 |